Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Expert Analyses of the following article:

FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents

Source: newsroom.lilly.com
John SpurlockMay 13, 2008
FDA approval of strattera in kids should be good news for Lilly
Author: John Spurlock, MD, Medical Director, Continence Management Institute of the LeHigh Valley
1. Lilly should be pleased with approval of Strattera in children and adolescents 2. Strattera is the superior agent for ADHD 3. approval should boost Liily sales
May 13, 2008
Lily's impact likely minimal
Author: GLG Expert Contributor
Strattera has been approved for "maintenance treatment" for ADHD, however this probably changes nothing for prescribers or patients.  Those who are on it will continue to take it, but no one will be changing to Strattera because of this new classification.
May 12, 2008
The pros and cons of Strattera driving marketing
Author: GLG Expert Contributor
Eli Lilly needs to find a compelling niche for Strattera since, in the treatment of ADHD, it is viewed as a less effective, though safer (because it cannot be abused), alternative to stimulants.
May 12, 2008
Will Strattera be around in 3 years?
Author: GLG Expert Contributor
My personal prediction is that this product will NOT be on the market in 3-5 years.  My clinical experience never approached that which the research would suggest.  I suspect that the "research" that was done on this product is frought with company incentives.
May 12, 2008
Important New Data for Children and Adolescents
Author: GLG Expert Contributor
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial
May 12, 2008
Will Not Meaningfully Change Prescribing Patterns
Author: GLG Expert Contributor
While this is new data from an 18 month study, the common practice already is to "stick with what works." Thus, if a child is started on Strattera (or another ADHD medication) and has positive results, the physician will most likely continue that drug.
May 12, 2008
does straterra work?
Author: GLG Expert Contributor
we really have had little luck with straterra in  our office.  Even at high  doses,  the drug rarely does the trick

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics